• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

诱导型一氧化氮合酶（iNOS）：为何两波新冠患者中其产生情况不同？

Inducible Nitric Oxide Synthase (iNOS): Why a Different Production in COVID-19 Patients of the Two Waves?

作者信息

Gelzo Monica, Scialò Filippo, Cacciapuoti Sara, Pinchera Biagio, De Rosa Annunziata, Cernera Gustavo, Comegna Marika, Tripodi Lorella, Schiano Moriello Nicola, Mormile Mauro, Fabbrocini Gabriella, Parrella Roberto, Corso Gaetano, Gentile Ivan, Castaldo Giuseppe

机构信息

Ceinge-Biotecnologie Avanzate s.c.a.r.l., 80145 Naples, Italy.

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy.

出版信息

Viruses. 2022 Mar 5;14(3):534. doi: 10.3390/v14030534.

DOI:10.3390/v14030534
PMID:35336941
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8948744/
Abstract

Profound clinical differences between the first and second waves of COVID-19 were observed in Europe. Nitric oxide (NO) may positively impact patients with Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2) infection. It is mainly generated by inducible nitric oxide synthase (iNOS). We studied serum iNOS levels together with serum interleukin (IL)-6 and IL-10 in patients with SARS-CoV-2 infection in the first wave ( = 35) and second wave ( = 153). In the first wave, serum iNOS, IL-6, IL-10 levels increased significantly, in line with the World Health Organization (WHO) score severity, while in the second wave, iNOS did not change with the severity. The patients of the second wave showed lower levels of iNOS, IL-6, and IL-10, as compared to the corresponding subgroup of the first wave, suggesting a less severe outcome of COVID-19 in these patients. However, in the severe patients of the second wave, iNOS levels were significantly lower in patients treated with steroids or azithromycin before the hospitalization, as compared to the untreated patients. This suggests an impairment of the defense mechanism against the virus and NO-based therapies as a potential therapy in patients with low iNOS levels.

摘要

在欧洲观察到了新冠疫情第一波和第二波之间深刻的临床差异。一氧化氮（NO）可能对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染患者产生积极影响。它主要由诱导型一氧化氮合酶（iNOS）产生。我们研究了第一波（n = 35）和第二波（n = 153）SARS-CoV-2感染患者的血清iNOS水平以及血清白细胞介素（IL）-6和IL-10水平。在第一波中，血清iNOS、IL-6、IL-10水平显著升高，与世界卫生组织（WHO）评分的严重程度一致，而在第二波中，iNOS水平并未随严重程度而变化。与第一波的相应亚组相比，第二波患者的iNOS、IL-6和IL-10水平较低，这表明这些患者的新冠病情较轻。然而，在第二波的重症患者中，与未治疗的患者相比，住院前接受类固醇或阿奇霉素治疗的患者iNOS水平显著较低。这表明针对病毒的防御机制受损，基于NO的疗法可能是iNOS水平较低患者的一种潜在治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d781/8948744/4c0694d78e96/viruses-14-00534-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d781/8948744/84c255070802/viruses-14-00534-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d781/8948744/4c0694d78e96/viruses-14-00534-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d781/8948744/84c255070802/viruses-14-00534-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d781/8948744/4c0694d78e96/viruses-14-00534-g002.jpg

相似文献

1
Inducible Nitric Oxide Synthase (iNOS): Why a Different Production in COVID-19 Patients of the Two Waves?诱导型一氧化氮合酶（iNOS）：为何两波新冠患者中其产生情况不同？
Viruses. 2022 Mar 5;14(3):534. doi: 10.3390/v14030534.
2
Implications of SARS-Cov-2 infection on eNOS and iNOS activity: Consequences for the respiratory and vascular systems.SARS-CoV-2 感染对 eNOS 和 iNOS 活性的影响：对呼吸系统和血管系统的影响。
Nitric Oxide. 2021 Jun 1;111-112:64-71. doi: 10.1016/j.niox.2021.04.003. Epub 2021 Apr 6.
3
Induction of nitric oxide synthase and over-production of nitric oxide by interleukin-1beta in cultured lacrimal gland acinar cells.白细胞介素-1β在培养的泪腺腺泡细胞中诱导一氧化氮合酶并导致一氧化氮过量产生。
Exp Eye Res. 2003 Jul;77(1):109-14. doi: 10.1016/s0014-4835(03)00058-7.
4
Increased IL-17A secreting CD4+ T cells, serum IL-17 levels and exhaled nitric oxide are correlated with childhood asthma severity.白细胞介素-17A 分泌的 CD4+T 细胞、血清白细胞介素-17 水平和呼出气一氧化氮与儿童哮喘严重程度相关。
Clin Exp Allergy. 2013 Sep;43(9):1018-26. doi: 10.1111/cea.12119.
5
Prolonged STAT1 activation is associated with interferon-gamma priming for interleukin-1-induced inducible nitric-oxide synthase expression by islets of Langerhans.STAT1的长期激活与胰岛对白细胞介素-1诱导的诱导型一氧化氮合酶表达的γ干扰素启动有关。
J Biol Chem. 1999 Oct 8;274(41):29266-73. doi: 10.1074/jbc.274.41.29266.
6
Essential role of nitric oxide and interferon-gamma for tumor immunotherapy with interleukin-10.一氧化氮和γ干扰素在白细胞介素-10肿瘤免疫治疗中的重要作用。
J Immunother. 2000 Mar-Apr;23(2):208-14. doi: 10.1097/00002371-200003000-00005.
7
Inducible nitric oxide synthase expression is inhibited by myeloperoxidase.诱导型一氧化氮合酶的表达受到髓过氧化物酶的抑制。
Nitric Oxide. 2005 Aug;13(1):42-53. doi: 10.1016/j.niox.2005.04.002.
8
The potential of BEN815 as an anti-inflammatory, antiviral and antioxidant agent for the treatment of COVID-19.BEN815作为一种抗炎、抗病毒和抗氧化剂用于治疗新型冠状病毒肺炎的潜力。
Phytomed Plus. 2021 Nov;1(4):100058. doi: 10.1016/j.phyplu.2021.100058. Epub 2021 Mar 18.
9
Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice.诱导型一氧化氮合酶（iNOS）对于白细胞介素-2诱导的小鼠低血压和血管渗漏综合征并非必需。
J Immunother. 2008 May;31(4):325-33. doi: 10.1097/CJI.0b013e31816112e8.
10
Dexamethasone inhibits inducible nitric-oxide synthase expression and nitric oxide production by destabilizing mRNA in lipopolysaccharide-treated macrophages.地塞米松通过使脂多糖处理的巨噬细胞中的mRNA不稳定来抑制诱导型一氧化氮合酶的表达和一氧化氮的产生。
Mol Pharmacol. 2002 Sep;62(3):698-704. doi: 10.1124/mol.62.3.698.

引用本文的文献

1
Serum HDL and their subfractions are impaired in multisystem inflammatory syndrome in children (MIS-C).儿童多系统炎症综合征（MIS-C）患者的血清高密度脂蛋白（HDL）及其亚组分受损。
J Transl Med. 2025 Jan 21;23(1):99. doi: 10.1186/s12967-025-06123-z.
2
Arterial stiffness in adults with Long COVID in sub-Saharan Africa.撒哈拉以南非洲地区长新冠成年人的动脉僵硬度。
Physiol Rep. 2024 Sep;12(17):e70029. doi: 10.14814/phy2.70029.
3
Integrating system biology and intratumor gene therapy by trans-complementing the appropriate co-stimulatory molecule as payload in oncolytic herpes virus.

本文引用的文献

1
The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: A systematic review and meta-analysis of randomized controlled trials.中和单克隆抗体对 COVID-19 门诊患者结局的影响：一项随机对照试验的系统评价和荟萃分析。
J Med Virol. 2022 May;94(5):2222-2229. doi: 10.1002/jmv.27623. Epub 2022 Feb 7.
2
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.瑞德西韦早期治疗可降低门诊患者重症 COVID-19 进展风险
N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22.
3
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
通过在溶瘤性疱疹病毒中作为有效载荷转互补合适的共刺激分子，将系统生物学与肿瘤内基因治疗相结合。
Cancer Gene Ther. 2024 Sep;31(9):1335-1343. doi: 10.1038/s41417-024-00790-8. Epub 2024 Jun 5.
4
VEGFR and DPP-IV as Markers of Severe COVID-19 and Predictors of ICU Admission.VEGFR 和 DPP-IV 作为严重 COVID-19 的标志物和 ICU 收治的预测因子。
Int J Mol Sci. 2023 Nov 30;24(23):17003. doi: 10.3390/ijms242317003.
5
Cytokine-Induced iNOS in A549 Alveolar Epithelial Cells: A Potential Role in COVID-19 Lung Pathology.细胞因子诱导的A549肺泡上皮细胞中的诱导型一氧化氮合酶：在COVID-19肺部病理中的潜在作用
Biomedicines. 2023 Oct 3;11(10):2699. doi: 10.3390/biomedicines11102699.
6
Inhaled Nitric Oxide in Acute Respiratory Distress Syndrome Subsets: Rationale and Clinical Applications.吸入一氧化氮治疗急性呼吸窘迫综合征亚组患者：原理与临床应用。
J Aerosol Med Pulm Drug Deliv. 2023 Jun;36(3):112-126. doi: 10.1089/jamp.2022.0058. Epub 2023 Apr 20.
7
Different cytokine and chemokine profiles in hospitalized patients with COVID-19 during the first and second outbreaks from Argentina show no association with clinical comorbidities.在阿根廷的第一波和第二波 COVID-19 疫情期间，住院患者的细胞因子和趋化因子谱不同，但与临床合并症无关。
Front Immunol. 2023 Feb 1;14:1111797. doi: 10.3389/fimmu.2023.1111797. eCollection 2023.
8
Combining L-Arginine with vitamin C improves long-COVID symptoms: The LINCOLN Survey.L-精氨酸联合维生素 C 可改善长新冠症状：林肯调查。
Pharmacol Res. 2022 Sep;183:106360. doi: 10.1016/j.phrs.2022.106360. Epub 2022 Jul 19.
莫努匹韦片用于非住院 COVID-19 患者的口服治疗。
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
4
Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports.新冠病毒：辉瑞公司报告称，其新冠口服药帕罗韦德对有重症风险的患者有效率达89%。
BMJ. 2021 Nov 8;375:n2713. doi: 10.1136/bmj.n2713.
5
Second versus first wave of COVID-19 deaths: Shifts in age distribution and in nursing home fatalities.第二波与第一波 COVID-19 死亡：年龄分布和养老院死亡人数的变化。
Environ Res. 2021 Apr;195:110856. doi: 10.1016/j.envres.2021.110856. Epub 2021 Feb 10.
6
Lombardy, Northern Italy: COVID-19 second wave less severe and deadly than the first? A preliminary investigation.意大利北部伦巴第地区：COVID-19 第二波疫情不如第一波严重和致命？初步调查。
Infect Dis (Lond). 2021 May;53(5):370-375. doi: 10.1080/23744235.2021.1884745. Epub 2021 Feb 9.
7
Nitric oxide and COVID-19: Dose, timing and how to administer it might be crucial.一氧化氮与新型冠状病毒肺炎：剂量、时机及给药方式可能至关重要。
Acta Anaesthesiol Scand. 2021 May;65(5):576-577. doi: 10.1111/aas.13788. Epub 2021 Mar 6.
8
Differences in the clinical characteristics of COVID-19 patients who died in hospital during different phases of the pandemic: national data from Italy.不同流行阶段住院 COVID-19 死亡患者的临床特征差异：意大利全国数据。
Aging Clin Exp Res. 2021 Jan;33(1):193-199. doi: 10.1007/s40520-020-01764-0. Epub 2020 Dec 21.
9
The Evolution of Covid-19 in Italy after the Spring of 2020: An Unpredicted Summer Respite Followed by a Second Wave.2020 年春季后意大利新冠病毒的演变：出乎意料的夏季暂歇，随后迎来第二波疫情。
Int J Environ Res Public Health. 2020 Nov 24;17(23):8708. doi: 10.3390/ijerph17238708.
10
Inhaled nitric oxide for critically ill Covid-19 patients: a prospective study.吸入一氧化氮治疗重症新冠患者：一项前瞻性研究。
Crit Care. 2020 Nov 12;24(1):645. doi: 10.1186/s13054-020-03371-x.